NCT02633839View on ClinicalTrials.gov

A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

June 30, 2016

Conditions
Smoking
Interventions
DRUG

CVT-301

Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.

DRUG

Carbidopa

Administered orally according to the carbidopa dosing schedule.

Trial Locations (2)

32117

Site 001, Daytona Beach

75247

Site 002, Dallas

Sponsors
All Listed Sponsors
lead

Acorda Therapeutics

INDUSTRY